Xenon Pharmaceuticals Inc (XENE)
$41.31
+0.01
(+0.02%)▲
Insights on Xenon Pharmaceuticals Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 8.76K → 5.38M (in $), with an average increase of 99.8% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -48.46M → -44.74M (in $), with an average increase of 8.3% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 47.0% return, outperforming this stock by 31.0%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 243.4% return, outperforming this stock by 133.0%
Performance
- $40.62$41.71$41.31
1.67%
Downside
Day's Volatility :2.61%
Upside
0.96%
- $27.99$50.99$41.31
32.24%
Downside
52 Weeks Volatility :45.11%
Upside
18.98%
Returns
| Period | Xenon Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -9.86% | -0.8% | 0.0% |
6 Months | 18.1% | 5.7% | 0.0% |
1 Year | 11.5% | 3.0% | -0.7% |
3 Years | 110.44% | 14.1% | -21.8% |
Highlights
Market Capitalization | 3.1B |
Book Value | $12.31 |
Earnings Per Share (EPS) | -2.73 |
PEG Ratio | -0.06 |
Wall Street Target Price | 58.1 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -15.57% |
Return On Equity TTM | -22.12% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | -96.3M |
EBITDA | -210.5M |
Diluted Eps TTM | -2.73 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.91 |
EPS Estimate Next Year | -3.29 |
EPS Estimate Current Quarter | -0.76 |
EPS Estimate Next Quarter | -0.75 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 40.64%
Technicals Summary
Sell
Neutral
Buy
Xenon Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Xenon Pharmaceuticals Inc | -3.68% | 18.1% | 11.5% | 110.44% | 356.46% |
 Moderna, Inc. | -0.38% | 12.96% | -27.86% | -39.2% | 336.75% |
 Regeneron Pharmaceuticals, Inc. | -6.39% | 6.51% | 9.62% | 78.78% | 144.38% |
 Novo Nordisk A/s | -6.76% | 22.49% | 44.85% | 243.36% | 401.52% |
 Vertex Pharmaceuticals Incorporated | -3.41% | 6.25% | 21.24% | 81.12% | 121.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Xenon Pharmaceuticals Inc | NA | NA | -0.06 | -2.91 | -0.22 | -0.16 | NA | 12.31 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.75 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.03 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.46 | 46.46 | 2.4 | 3.31 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.57 | 28.57 | 0.53 | 16.62 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Xenon Pharmaceuticals Inc | Buy | $3.1B | 356.46% | NA | 0.0% |
Moderna, Inc. | Buy | $40.3B | 336.75% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.3B | 144.38% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $564.6B | 401.52% | 46.46 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $102.5B | 121.07% | 28.57 | 36.68% |
Institutional Holdings
venBio Select Advisor LLC
7.51%FMR Inc
7.50%Driehaus Capital Management LLC
5.76%Wellington Management Company LLP
5.52%Polar Capital Holdings PLC
4.07%Capital World Investors
3.55%
Corporate Announcements
Xenon Pharmaceuticals Inc Earnings
Xenon Pharmaceuticals Inc’s price-to-earnings ratio stands at None
Read More
Company Information
xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
Organization | Xenon Pharmaceuticals Inc |
Employees | 251 |
CEO | Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. |
Industry | Health Technology |
Discover More
Tfs Financial Corp
$41.31
+0.02%
Korn/ferry International
$41.31
+0.02%
Ishares Msci Eafe Min Vol Factor Etf
$41.31
+0.02%
Berry Plastics Group, Inc.
$41.31
+0.02%
Mdu Resources Group Inc.
$41.31
+0.02%
Banco Macro S.a.
$41.31
+0.02%
Fidelity High Dividend Etf
$41.31
+0.02%
Ero Copper Corp
$41.31
+0.02%
Piper Jaffray Cos
$41.31
+0.02%